Search results for " 2"

showing 10 items of 10825 documents

Apoptotic Activity of MeCP2 Is Enhanced by C-Terminal Truncating Mutations.

2016

Methyl-CpG binding protein 2 (MeCP2) is a widely abundant, multifunctional protein most highly expressed in post-mitotic neurons. Mutations causing Rett syndrome and related neurodevelopmental disorders have been identified along the entire MECP2 locus, but symptoms vary depending on mutation type and location. C-terminal mutations are prevalent, but little is known about the function of the MeCP2 C-terminus. We employ the genetic efficiency of Drosophila to provide evidence that expression of p.Arg294* (more commonly identified as R294X), a human MECP2 E2 mutant allele causing truncation of the C-terminal domains, promotes apoptosis of identified neurons in vivo. We confirm this novel find…

0301 basic medicineMethyl-CpG-Binding Protein 2lcsh:MedicineApoptosisBiochemistryPhosphoserine0302 clinical medicineAnimal CellsDrosophila ProteinsPost-Translational ModificationPhosphorylationlcsh:ScienceNeuronsMotor NeuronsGeneticsMultidisciplinaryCell DeathbiologyDrosophila MelanogasterAnimal ModelsInsectsFOXG1Cell ProcessesCaspasesPhosphorylationDrosophilaBiological CulturesCellular TypesDrosophila melanogasterResearch ArticleGene isoformcongenital hereditary and neonatal diseases and abnormalitiesArthropodaProtein domainMouse ModelsMotor ActivityResearch and Analysis MethodsTransfectionModels BiologicalMECP203 medical and health sciencesModel OrganismsProtein Domainsmental disordersAnimalsHumansMolecular Biology TechniquesImmunohistochemistry TechniquesMolecular BiologyTranscription factorBinding proteinlcsh:ROrganismsBiology and Life SciencesProteinsCell BiologyCell Culturesbiology.organism_classificationInvertebratesHistochemistry and Cytochemistry TechniquesHEK293 Cells030104 developmental biologyCellular NeuroscienceMutationImmunologic TechniquesMutant Proteinslcsh:Q030217 neurology & neurosurgeryNeuroscienceTranscription FactorsPLoS ONE
researchProduct

The usefulness of NEWS2 at day 7 of hospitalization in predicting COVID-19 evolution and as an early endpoint in therapeutic trials

2021

Highlights • There is a need for reliable tools to predict the evolution of hospitalized patients suffering from COVID-19 • The likelihood of unfavourable evolution for patients hospitalized for COVID-19 with a National • Early Warning Score 2 (NEWS2) below 7 at Day 7 of hospitalization is nearly non-existent • Such a score could thus be used to allow earlier discharge of the patients and as a judgement criterion in therapeutic trials

0301 basic medicineMicrobiology (medical)2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNEWS2Communicable DiseasesArticle03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineIntensive care medicineUnfavourable eventAgedbusiness.industrySARS-CoV-2COVID-19Therapeutic trialCoronavirusHospitalizationInfectious DiseasesItalySARS-CoV2businessPredictionThe Journal of Infection
researchProduct

Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patien…

2021

Objectives There is limited information on the performance of rapid antigen detection (RAD) tests to identify SARS-CoV-2-infected asymptomatic individuals. In this field study, we evaluated the Panbio™ COVID-19 Ag Rapid Test Device (Abbott Diagnostics, Jena, Germany) for this purpose. Methods A total of 634 individuals (355 female; median age, 37 years; range, 9–87) were enrolled. Two nasopharyngeal swabs were collected from household (n = 338) and non-household contacts (n = 296) of COVID-19 cases. RAD testing was carried out at the point of care. The RT-PCR test used was the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, MA, USA). Results Household contacts were tested at a median …

0301 basic medicineMicrobiology (medical)AdultMale2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Rapid antigen detection testAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Point-of-Care Systems030106 microbiologyTest sensitivityImmunologic TestsAsymptomaticSensitivity and Specificity03 medical and health sciencesYoung Adult0302 clinical medicineCOVID-19 TestingInternal medicineMedicineHumans030212 general & internal medicineChildAntigens ViralAsymptomatic InfectionsAgedAged 80 and overImmunoassayFamily Characteristicsbusiness.industrySARS-CoV-2COVID-19General MedicineMiddle AgedTest (assessment)AsymptomaticResearch NoteInfectious DiseasesRapid antigen testCOVID-19 Nucleic Acid TestingClose contactsFemalemedicine.symptomContact TracingbusinessContact tracingClinical Microbiology and Infection
researchProduct

Lactic Acid Bacteria With Antioxidant Activities Alleviating Oxidized Oil Induced Hepatic Injury in Mice

2018

In order to screening new Lactic acid bacteria (LAB) strains to alleviating liver injury induced by oxidized oil, we isolated and screened LAB from Chinese fermented foods. Lactobacillus plantarum AR113, Pediococcus pentosaceus AR243, and Lactobacillus plantarum AR501 showed higher scavenging activity of α, α-Diphenyl-β-Picrylhydrazyl (DPPH) free radical and hydrogen radical, stronger inhibition of lipid peroxidation, and better protective effect on yeast cells in vitro. In vivo, oral administration of L. plantarum AR501 improved the antioxidant status of injury mice induced by oxidized oil including decreasing lipid peroxidation, recovering activities of antioxidant enzymes. Meanwhile, the…

0301 basic medicineMicrobiology (medical)AntioxidantantioxidantDPPHmedicine.medical_treatmentlcsh:QR1-502oxidative damageMicrobiologylcsh:MicrobiologyLipid peroxidation03 medical and health scienceschemistry.chemical_compoundmedicineLactic acid bacteriaOriginal Researchhepatic injuryLiver injurybiologyfood and beveragesoxidized oilGlutathionebiology.organism_classificationmedicine.diseaseLactic acid030104 developmental biologyBiochemistrychemistrynuclear factor erythroid 2-related factor 2Lactobacillus plantarumBacteriaFrontiers in Microbiology
researchProduct

One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages.

2021

The COVID-19 pandemic was officially declared on March 11th, 2020. Since the very beginning, the spread of the virus has been tracked nearly in real-time by worldwide genome sequencing efforts. As of March 2021, more than 830,000 SARS-CoV-2 genomes have been uploaded in GISAID and this wealth of data allowed researchers to study the evolution of SARS-CoV-2 during this first pandemic year. In parallel, nomenclatures systems, often with poor consistency among each other, have been developed to designate emerging viral lineages. Despite general fears that the virus might mutate to become more virulent or transmissible, SARS-CoV-2 genetic diversity has remained relatively low during the first ~…

0301 basic medicineMicrobiology (medical)COVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyReviewBiologyMicrobiologyGenomeVirusDNA sequencing03 medical and health sciencesVACCINESGenetic variationPandemicGeneticsHumansLineagesMolecular BiologyEcology Evolution Behavior and SystematicsTransmission (medicine)SARS-CoV-2VaccinationVariantsGenetic VariationCOVID-19Biological EvolutionVaccination030104 developmental biologyInfectious DiseasesEvolutionary biologyDiagnostic tests
researchProduct

Early detection of SARS-CoV-2 infection cases or outbreaks at nursing homes by targeted wastewater tracking

2021

Objectives Near-source tracking of SARS-CoV-2 RNA in the sewage drains serving particular buildings may allow rapid identification of SARS-CoV-2 infection cases or local outbreaks. In this pilot study, we investigated whether this was the case for nursing homes (NH). Methods The study involved five NH (from A to E) affiliated to the Clínico-Malvarrosa Health Department, Valencia (Spain). These were nursing or mixed nursing/care homes of different sizes, altogether providing care for 472 residents attended by a staff of 309. Near-source sewage samples were screened for presence of SARS-CoV-2 RNA by RT-qPCR at least 5 days per week during the study period. SARS-CoV-2 RNA testing in nasopharyn…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCOVID-19 outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNursing homesEarly detectionSewageWastewater03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineSanitary sewerskin and connective tissue diseasesLetter to the EditorAgedSARS-CoV-2business.industryfungiCOVID-19OutbreakGeneral MedicineSARS-CoV-2 RNANursing Homesbody regionsInfectious DiseasesWastewaterEmergency medicineWater MicrobiologyNursing homesbusinessNear-source tracking
researchProduct

Point-of-care evaluation of a rapid antigen test (CLINITESTⓇ Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and as…

2021

AbstractRapid antigen assays (RAD) based on lateral flow immunochromatography (LFIC) technology have emerged as a valuable tool for the control of COVID-19 pandemic. Manufacturer□independent, real□world evaluation of these assays is crucial given the considerable heterogeneity reported in their clinical and analytical performances. Here, we report for the first time on the point-of-care performance of the CLINITEST® Rapid COVID-19 Antigen Test (Siemens, Healthineers, Erlangen, Germany) to detect SARS-CoV-2 infection in presumptive COVID-19 cases or asymptomatic close contacts of COVID-19 patients. When compared to RT-PCR, the overall sensitivity of the assay was 80.2 (95% CI, 70.9-87.1) for…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCopper SulfateCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Point-of-Care Systems030106 microbiologyPopulationAsymptomaticSensitivity and SpecificityCitric Acid03 medical and health sciences0302 clinical medicineInternal medicineAntigen assaysmedicineHumans030212 general & internal medicineeducationLetter to the EditorPoint of careeducation.field_of_studybusiness.industrySARS-CoV-2COVID-19Antigen testInfectious DiseasesSodium BicarbonateRapid antigen testmedicine.symptombusinessThe Journal of Infection
researchProduct

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

2021

Abstract Scope Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. Methods The panel conducted a detailed review of the literature and eventual press rele…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyCoronavirupractice guidelines as topiccoronavirusrandomized controlled trials as topicGuidelinesmedicine.disease_causemedicallaw.invention03 medical and health sciences0302 clinical medicinesocietiesRandomized controlled triallawPandemicitalymedicinepneumonia030212 general & internal medicineIntensive care medicinehumansSocieties MedicalCoronavirustherapySARS-CoV-2business.industryCOVID-19; Coronavirus; Pneumonia; SARS-CoV-2; TherapyStandard treatmentCOVID-19PneumoniaGeneral Medicinecovid-19; coronavirus; pneumonia; sars-cov-2; therapy; covid-19; humans; italy; randomized controlled trials as topic; sars-cov-2; societies medical; standard of care; practice guidelines as topicCOVID-19 Drug TreatmentCoronavirusClinical trialsars-cov-2Infectious Diseasescovid-19standard of carePosition paperObservational studyTherapyCoronavirus; COVID-19; Pneumonia; SARS-CoV-2; TherapybusinessHuman
researchProduct

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

2021

Introduction: In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization's elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for HCV, approved for 8-week treatment in patients without cirrhosis, and with compensated cirrhosis (CC). Previously, 12 weeks of therapy was recommended for patients with CC. Shortened treatment may reduce the burden on healthcare resources, allowing more patients to be treated. This study presents the benefits that 8-week vs 12-week treatment with G/P may have in Italy. Methods: A multicohort Marko…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationTreatment duration030106 microbiologyPopulationTreatment duration03 medical and health sciences0302 clinical medicineHealth careTreatment duration.Medicine030212 general & internal medicineeducationOriginal ResearchHepatitis C viruseducation.field_of_studyGlecaprevir/pibrentasvirbusiness.industryGlecaprevirPibrentasvirInfectious DiseasesItalyEmergency medicineObservational studyGlecaprevir / pibrentasvirHepatitis C virubusinessInfectious Diseases and Therapy
researchProduct

The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives

2021

INTRODUCTION: The COVID-19 pandemic has dramatically challenged the national health systems worldwide in the last months. Dalbavancin is a novel antibiotic with a long plasmatic half-life and simplified weekly administration regimens, thus representing a promising option for the outpatient treatment of Gram-positive infections and the early discharge of hospitalized patients. Dalbavancin is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Many preliminary data seem to support its use in other indications, such as osteomyelitis, prosthetic joint infections, and infective endocarditis. AREAS COVERED: A search in the literature using validated keyword…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.drug_classProsthetic joint030106 microbiologyAntibioticsGram-Positive Bacterial InfectionABSSSIsMicrobiologyDrug Administration Scheduleosteomyelitis.endocarditi03 medical and health sciencesABSSSIs; COVID-19; dalbavancin; endocarditis; Gram-positive; long-acting; osteomyelitisGram-positive0302 clinical medicineVirologyPandemicAnti-Bacterial AgentmedicineAmbulatory CareAnimalsHumans030212 general & internal medicineIntensive care medicineGram-Positive Bacterial Infectionsbusiness.industryAnimalOsteomyelitisDalbavancinCOVID-19osteomyelitisSkin Diseases Bacteriallong-actingABSSSImedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesInfective endocarditisSkin structureendocarditisosteomyelitiTeicoplaninbusinessdalbavancinHuman
researchProduct